首页> 外文期刊>Stem cells and development >Effects of allogeneic hematopoietic stem cell transplantation plus thymus transplantation on malignant tumors: comparison between fetal, newborn, and adult mice.
【24h】

Effects of allogeneic hematopoietic stem cell transplantation plus thymus transplantation on malignant tumors: comparison between fetal, newborn, and adult mice.

机译:同种异体造血干细胞移植加胸腺移植对恶性肿瘤的影响:胎儿,新生和成年小鼠的比较。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

We have recently shown that allogeneic intrabone marrow-bone marrow transplantation + adult thymus transplantation (TT) is effective for hosts with malignant tumors. However, since thymic and hematopoietic cell functions differ with age, the most effective age for such intervention needed to be determined. We performed hematopoietic stem cell transplantation (HSCT) using the intrabone marrow method with or without TT from fetal, newborn, and adult B6 mice (H-2(b)) into BALB/c mice (H-2(d)) bearing Meth-A sarcoma (H-2(d)). The mice treated with all types of HSCT + TT showed more pronounced regression and longer survival than those treated with HSCT alone in all age groups. Those treated with HSCT + TT showed increased numbers of CD4(+) and CD8(+) T cells but decreased numbers of Gr-1/Mac-1 myeloid suppressor cells and decreased percentages of FoxP3 cells in CD4(+) T cells, compared with those treated with HSCT alone. In all mice, those treated with fetal liver cell (as fetal HSCs) transplantation + fetal TT or with newborn liver cell (as newborn HSCs) transplantation (NLT) + newborn TT (NTT) showed the most regression, and the latter showed the longest survival. The number of Gr-1/Mac-1 cells was the lowest, whereas the percentage of CD62L(-)CD44(+) effector memory T cells and the production of interferon gamma (IFN-gamma) were highest in the mice treated with NLT + NTT. These findings indicate that, at any age, HSCT + TT is more effective against cancer than HSCT alone and that NLT + NTT is most effective.
机译:我们最近显示,同种异体骨髓内骨髓移植+成人胸腺移植(TT)对于患有恶性肿瘤的宿主有效。但是,由于胸腺和造血细胞功能随年龄而异,因此需要确定这种干预的最有效年龄。我们采用骨髓内方法将造血干细胞移植(HSCT)与有或无TT从胎儿,新生和成年B6小鼠(H-2(b))移植到携带Meth的BALB / c小鼠(H-2(d))中-肉瘤(H-2(d))。与所有年龄组中单独使用HSCT治疗的小鼠相比,使用所有类型的HSCT + TT治疗的小鼠均表现出更明显的消退和更长的生存期。与HSCT + TT治疗的相比,CD4(+)和CD8(+)T细胞数量增加,但Gr-1 / Mac-1髓样抑制细胞数量减少,而CD4(+)T细胞中FoxP3细胞的百分比降低。与那些仅接受HSCT治疗的患者。在所有小鼠中,用胎肝细胞(作为胎儿HSC)移植+胎儿TT或新生儿肝细胞(作为新生儿HSC)移植(NLT)+新生儿TT(NTT)处理的小鼠表现出最大的退化,而后者表现出最长的退化。生存。在用NLT处理的小鼠中,Gr-1 / Mac-1细胞的数量最低,而CD62L(-)CD44(+)效应记忆T细胞的百分比和干扰素γ(IFN-γ)的产生最高+ NTT。这些发现表明,在任何年龄,HSCT + TT都比单独的HSCT更有效地抗癌,并且NLT + NTT最为有效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号